Last reviewed · How we verify
NCT06936332
Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne
NA trial testing Omnilux Clear Light Emitting Diode Treatment in Acne in 30 participants. Completed in 10 April 2025.
10 March 2025
Quick facts
| Lead sponsor | Ablon Skin Institute Research Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 18 November 2024 |
| Primary completion | 10 March 2025 |
| Estimated completion | 10 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Omnilux Clear Light Emitting Diode Treatment
Conditions studied
- Acne — all drugs for Acne →
Sponsor
Ablon Skin Institute Research Center
Who can join
14 and older, any sex, with Acne. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to further substantiate the effectiveness and safety of Omnilux Clear as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults 14 years of age or older over the course of 7 weeks. Participants will be screened to determine eligibility, assessed, instructed on how to use the Omnilux Clear and then treated with Omnilux Clear under the direction of the study staff during the first office visit. The first treatment will also act as a photosensitivity "patch" test to evaluate the participant for any unknown hereditary photosensitivity conditions or allergies to surface contacting materials. The particpants will then treat their face with the Omnilux Clear device at home 4 times per week for the first 6 weeks of the trial. The treatments are 10 minutes in duration. Participants will return to the study site at week 3 and week 7 for assessments, photographs and questionnaires.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06936332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acne
Currently open trials in the same condition.
- NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
- NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
- NCT06989840 — Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne · Phase 1 · recruiting
- NCT07368764 — The Suitability of Tience® for Treating Acne Scars · NA · recruiting
- NCT06909344 — 577-nm Diode Laser in the Treatment of Non -Inflammatory Acne · NA · recruiting
Other Ablon Skin Institute Research Center trials
Trials by the same sponsor.
- NCT06571799 — Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning Hair · NA · completed
- NCT05879406 — A Study to Evaluate the Efficacy and Safety of Clear Skin Formula on Mitigating Mild to Moderate Non-cystic Acne · NA · completed
- NCT06043102 — Study Evaluating the Efficacy and Safety of TheraClearX on Mitigating Mild to Moderate Acne · NA · completed
- NCT04048031 — Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women W · NA · completed
- NCT03206567 — Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06936332 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ablon Skin Institute Research Center
- Last refreshed: 20 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing